PMID- 37640105
OWN - NLM
STAT- MEDLINE
DCOM- 20231128
LR  - 20240205
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 34
IP  - 12
DP  - 2023 Dec
TI  - Predictive Partition Dosimetry and Outcomes after Yttrium-90 Resin Microsphere 
      Radioembolization of Colorectal Cancer Metastatic to the Liver: A Retrospective 
      Analysis.
PG  - 2138-2146
LID - S1051-0443(23)00643-7 [pii]
LID - 10.1016/j.jvir.2023.08.031 [doi]
AB  - PURPOSE: To characterize estimated absorbed tumor dose (AD(T)), objective 
      response (OR), and estimated target dose of liver metastatic colorectal cancer 
      (mCRC) after resin microsphere yttrium-90 ((90)Y) radioembolization using 
      partition dosimetry. MATERIALS AND METHODS: In this retrospective, single-center 
      study, multicompartment dosimetry of index tumors undergoing (90)Y 
      radioembolization from October 2013 to July 2022 was performed using MIM SurePlan 
      and pretreatment technetium-99m macroaggregated albumin infusion data. 
      Thirty-eight patients with mCRC underwent treatments for 59 index tumors. 
      Patients were imaged every 2-3 months after treatment and then every 3-6 months 
      after disease control to determine the best response per Response Evaluation 
      Criteria in Solid Tumors 1.1. Responses were categorized as OR or nonresponse 
      (NR). A Cox proportional hazards model evaluated the probability of tumor OR and 
      local progression-free survival (LPFS) based on AD(T). RESULTS: Patients had a 
      median follow-up of 116 days (interquartile range [IQR], 69-231 days). The AD(T) 
      was higher for OR patients than for NR patients (median, 130.8 [IQR, 85.6-239.0] 
      vs 40.6 [IQR, 26.0-66.3] Gy; P < .001). A greater percentage of OR than NR 
      patients were treated with activities calculated by partition modeling (54% vs 
      12%; P = .005). Only AD(T) predicted response (P = .032). At 6 months, an AD(T) 
      of 120 Gy predicted a 55% (95% CI, 0.0%-89%) probability of OR. Only AD(T) (P = 
      .010) and female sex (P = .014) predicted LPFS. At 1 year, an AD(T) of 120 Gy 
      predicted a 70% (95% CI, 35%-100%) probability of LPFS. CONCLUSIONS: Tumor dose 
      was the strongest predictor of OR for mCRC. Administration of an estimated 120 Gy 
      to mCRC predicted 55% OR with (90)Y resin microspheres at 6 months.
CI  - Copyright (c) 2023 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Doyle, Patrick W
AU  - Doyle PW
AD  - Vanderbilt University School of Medicine, Nashville, Tennessee.
FAU - Workman, C Spencer
AU  - Workman CS
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Shah, Neal
AU  - Shah N
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - McGonigle, Trey W
AU  - McGonigle TW
AD  - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Grice, Jared V
AU  - Grice JV
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Huang, Shi
AU  - Huang S
AD  - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Borgmann, Anthony J
AU  - Borgmann AJ
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Baker, Jennifer C
AU  - Baker JC
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Guys, Nicholas P
AU  - Guys NP
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Taylor, Jason E
AU  - Taylor JE
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Brown, Daniel B
AU  - Brown DB
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, 
      Tennessee. Electronic address: Daniel.b.brown@vumc.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230826
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 1K8M7UR6O1 (Yttrium-90)
RN  - 0 (Technetium Tc 99m Aggregated Albumin)
RN  - 0 (Yttrium Radioisotopes)
SB  - IM
MH  - Humans
MH  - Female
MH  - Microspheres
MH  - Retrospective Studies
MH  - Technetium Tc 99m Aggregated Albumin
MH  - *Liver Neoplasms/diagnostic imaging/radiotherapy
MH  - Yttrium Radioisotopes/adverse effects
MH  - *Embolization, Therapeutic/adverse effects/methods
MH  - *Colorectal Neoplasms
EDAT- 2023/08/29 00:42
MHDA- 2023/11/28 06:42
CRDT- 2023/08/28 19:20
PHST- 2023/04/05 00:00 [received]
PHST- 2023/06/26 00:00 [revised]
PHST- 2023/08/21 00:00 [accepted]
PHST- 2023/11/28 06:42 [medline]
PHST- 2023/08/29 00:42 [pubmed]
PHST- 2023/08/28 19:20 [entrez]
AID - S1051-0443(23)00643-7 [pii]
AID - 10.1016/j.jvir.2023.08.031 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2023 Dec;34(12):2138-2146. doi: 10.1016/j.jvir.2023.08.031. 
      Epub 2023 Aug 26.